Ignite Creation Date:
2024-05-06 @ 7:14 PM
Last Modification Date:
2024-10-26 @ 3:03 PM
Study NCT ID:
NCT05947448
Status:
RECRUITING
Last Update Posted:
2024-04-01
First Post:
2023-07-07
Brief Title:
Efficacy and Safety of Mexartan Potassium Tablets AZL-M and Calcium Channel Blockers CCB in the Treatment of Adults With Essential Hypertension in Chinese Population a National Multicenter Prospective Observational Study
Sponsor:
Hasten Biopharmaceutical Co Ltd
Organization:
Hasten Biopharmaceutical Co Ltd
Study Overview
Official Title:
Efficacy and Safety of Mexartan Potassium Tablets AZL-M and Calcium Channel Blockers CCB in the Treatment of Adults With Essential Hypertension in Chinese Population a National Multicenter Prospective Observational Study
Status:
RECRUITING
Status Verified Date:
2023-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a national multicenter prospective observational study It is planned to enroll 1215 patients with newly diagnosed essential hypertension in 80 centers and divide them into 3 groups according to different treatment plans given by doctors AZL-M monotherapy group CCB monotherapy group amlodipine besylate tablets or nifedipine controlled-release tablets and AZL-MCCB amlodipine besylate tablets or nifedipine controlled-release tablets combined treatment group Subjects were visited 4 times at baseline 1 month 3 months and 6 months and the following key indicators of subjects were measured according to the doctors decision and the measurement results were collected
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None